SPOTLIGHT: BMS a takeover target?

BMS a takeover target?
Analysts are salivating over Bristol-Myers Squibb. Healthy earnings and sales growth, coupled with a stock price down by about a third since last July, makes the drug maker "an attractive takeover candidate for a larger pharma," according to a Zacks Investment Research analyst. Report

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.